Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

P90 ribosomal S6 kinases : A bona fide target for novel targeted anticancer therapies?

Koutsougianni, Fani ; Alexopoulou, Dimitra ; Uvez, Ayca ; Lamprianidou, Andromachi ; Sereti, Evangelia LU ; Tsimplouli, Chrisiida ; Ilkay Armutak, Elif and Dimas, Konstantinos (2023) In Biochemical Pharmacology 210.
Abstract

The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of highly conserved Ser/Thr kinases. They are downstream effectors of the Ras/ERK/MAPK signaling cascade. ERK1/2 activation directly results in the phosphorylation of RSKs, which further, through interaction with a variety of different downstream substrates, activate various signaling events. In this context, they have been shown to mediate diverse cellular processes like cell survival, growth, proliferation, EMT, invasion, and metastasis. Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have... (More)

The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of highly conserved Ser/Thr kinases. They are downstream effectors of the Ras/ERK/MAPK signaling cascade. ERK1/2 activation directly results in the phosphorylation of RSKs, which further, through interaction with a variety of different downstream substrates, activate various signaling events. In this context, they have been shown to mediate diverse cellular processes like cell survival, growth, proliferation, EMT, invasion, and metastasis. Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have occurred, such as biological insights, function, and mechanisms associated with carcinogenesis. We additionally present and discuss the recent advances but also the limitations in the development of pharmacological inhibitors of RSKs, in the context of the use of these kinases as putative, more efficient targets for novel anticancer therapeutic approaches.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cancer, Inhibitors, P90 ribosomal s6 kinases, Signaling, Targeted therapy
in
Biochemical Pharmacology
volume
210
article number
115488
publisher
Elsevier
external identifiers
  • pmid:36889445
  • scopus:85149893072
ISSN
0006-2952
DOI
10.1016/j.bcp.2023.115488
language
English
LU publication?
yes
id
0f70ad6d-274b-454b-9b8d-9591caed6bfb
date added to LUP
2023-04-24 13:47:41
date last changed
2024-06-29 03:19:19
@article{0f70ad6d-274b-454b-9b8d-9591caed6bfb,
  abstract     = {{<p>The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of highly conserved Ser/Thr kinases. They are downstream effectors of the Ras/ERK/MAPK signaling cascade. ERK1/2 activation directly results in the phosphorylation of RSKs, which further, through interaction with a variety of different downstream substrates, activate various signaling events. In this context, they have been shown to mediate diverse cellular processes like cell survival, growth, proliferation, EMT, invasion, and metastasis. Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have occurred, such as biological insights, function, and mechanisms associated with carcinogenesis. We additionally present and discuss the recent advances but also the limitations in the development of pharmacological inhibitors of RSKs, in the context of the use of these kinases as putative, more efficient targets for novel anticancer therapeutic approaches.</p>}},
  author       = {{Koutsougianni, Fani and Alexopoulou, Dimitra and Uvez, Ayca and Lamprianidou, Andromachi and Sereti, Evangelia and Tsimplouli, Chrisiida and Ilkay Armutak, Elif and Dimas, Konstantinos}},
  issn         = {{0006-2952}},
  keywords     = {{Cancer; Inhibitors; P90 ribosomal s6 kinases; Signaling; Targeted therapy}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Biochemical Pharmacology}},
  title        = {{P90 ribosomal S6 kinases : A bona fide target for novel targeted anticancer therapies?}},
  url          = {{http://dx.doi.org/10.1016/j.bcp.2023.115488}},
  doi          = {{10.1016/j.bcp.2023.115488}},
  volume       = {{210}},
  year         = {{2023}},
}